Marie-Eve Isner-Horobeti
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Marie-Eve Isner-Horobeti has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
B. Geny
2 shared publicationsE. Lonsdorfer
2 shared publicationsF. Favret
2 shared publicationsJehan Lecocq
Université de Strasbourg, institut universitaire de réadaptation Clémenceau-Strasbourg, médecine physique et de réadaptation, Strasbourg, France
2 shared publicationsA. Charton
Strasbourg University, EA 3072
1 shared publicationChristophe Enaux
Université de Strasbourg, faculté de géographie, UMR 7362, Strasbourg, France
1 shared publication
Latest Publications
- 26 September 2017
- Published by Elsevier in Annals of Physical and Rehabilitation Medicine
- Vol. 60, e74
Follow-up and adherence to two different programs of physical fitness for fibromyalgia patients: Preliminary results
- 26 September 2017
- Published by Elsevier in Annals of Physical and Rehabilitation Medicine
- Vol. 60, e74
Follow-up and adherence to two different programs of physical fitness for fibromyalgia patients: Preliminary results
- 1 September 2015
- Published by Elsevier in Annals of Physical and Rehabilitation Medicine
- Vol. 58, e96
Effect of aerobic and resistance training over a 6-weeks day hospital period on body fat in moderately to severely obese patients
- 1 September 2015
- Published by Elsevier in Annals of Physical and Rehabilitation Medicine
- Vol. 58, e96
Effect of aerobic and resistance training over a 6-weeks day hospital period on body fat in moderately to severely obese patients
- 1 April 2014
- Published by Elsevier in Revue Neurologique
- Vol. 170, A221
Intérêt du ré-entraînement à l’effort chez les patients atteints de sclérose en plaques
- 1 April 2014
- Published by Elsevier in Revue Neurologique
- Vol. 170, A221
Intérêt du ré-entraînement à l’effort chez les patients atteints de sclérose en plaques
- 22 January 2014
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 114 (5) , 885-889
Microbiopsies versus Bergström needle for skeletal muscle sampling: impact on maximal mitochondrial respiration rate
Microbiopsies are increasingly used as an alternative to the standard Bergström technique for skeletal muscle sampling. The potential impact of these two different procedures on mitochondrial respiration rate is unknown. The objective of this work was to compare microbiopsies versus Bergström procedure on mitochondrial respiration in skeletal muscle. 52 vastus lateralis muscle samples were obtained from 13 anesthetized pigs, either with a Bergström [6 gauges (G)] needle or with microbiopsy needles (12, 14, 18G). Maximal mitochondrial respiration (V GM-ADP) was assessed using an oxygraphic method on permeabilized fibers. The weight of the muscle samples and V GM-ADP decreased with the increasing gauge of the needles. A positive nonlinear relationship was observed between the weight of the muscle sample and the level of maximal mitochondrial respiration (r = 0.99, p r = 0.99, p Microbiopsies give lower muscle sample weight and maximal rate of mitochondrial respiration compared to the standard Bergström needle.Therefore, the higher the gauge (i.e. the smaller the size) of the microbiopsy needle, the lower is the maximal rate of respiration. Microbiopsies of skeletal muscle underestimate the maximal mitochondrial respiration rate, and this finding needs to be highlighted for adequate interpretation and comparison with literature data.
- 22 January 2014
- Published by Springer Nature in European Journal of Applied Physiology
- Vol. 114 (5) , 885-889
Microbiopsies versus Bergström needle for skeletal muscle sampling: impact on maximal mitochondrial respiration rate
Microbiopsies are increasingly used as an alternative to the standard Bergström technique for skeletal muscle sampling. The potential impact of these two different procedures on mitochondrial respiration rate is unknown. The objective of this work was to compare microbiopsies versus Bergström procedure on mitochondrial respiration in skeletal muscle. 52 vastus lateralis muscle samples were obtained from 13 anesthetized pigs, either with a Bergström [6 gauges (G)] needle or with microbiopsy needles (12, 14, 18G). Maximal mitochondrial respiration (V GM-ADP) was assessed using an oxygraphic method on permeabilized fibers. The weight of the muscle samples and V GM-ADP decreased with the increasing gauge of the needles. A positive nonlinear relationship was observed between the weight of the muscle sample and the level of maximal mitochondrial respiration (r = 0.99, p r = 0.99, p Microbiopsies give lower muscle sample weight and maximal rate of mitochondrial respiration compared to the standard Bergström needle.Therefore, the higher the gauge (i.e. the smaller the size) of the microbiopsy needle, the lower is the maximal rate of respiration. Microbiopsies of skeletal muscle underestimate the maximal mitochondrial respiration rate, and this finding needs to be highlighted for adequate interpretation and comparison with literature data.
- 22 August 2013
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 41 (11) , 2558-2566
Intramuscular Pressure Before and After Botulinum Toxin in Chronic Exertional Compartment Syndrome of the Leg
Background: Botulinum toxin A (BoNT-A) is used in the treatment of muscle hypertrophy but has never been used in chronic exertional compartment syndrome (CECS). The objective diagnostic criterion in this condition is an abnormally elevated intramuscular pressure (IMP) in the compartment. In this study, the IMP was measured 1 minute (P1) and 5 minutes (P5) after the exercise was stopped before and after BoNT-A injection. Hypothesis: Botulinum toxin A reduces the IMP (P1 and P5) and eliminates the pain associated with CECS. Study Design: Case series; Level of evidence, 4. Methods: Botulinum toxin A was injected into the muscles of moderately trained patients with an anterior or anterolateral exertional compartment syndrome of the leg. The BoNT-A dose (mean ± SD) ranged from 76 ± 7 to 108 ± 10 U per muscle, depending on which of the 5 muscles in the 2 compartments were injected. The primary end point was IMP (P1, P5). Secondary end points were exertional pain, muscle strength, and safety. Follow-up was conducted up to 9 months. Results: A total of 25 anterior compartments and 17 lateral compartments were injected in 16 patients. The time interval (mean ± SD) between the BoNT-A injection and after BoNT-A injection IMP measurement was 4.4 ± 1.6 months (range, 3-9 months). In the anterior compartment, P1 and P5 fell by 63% ± 17% (P < .00001) and 59% ± 24% (P < .0001), respectively; in the lateral compartment, P1 and P5 fell by 68% ± 21% (P < .001) and 63% ± 21% (P < .01), respectively. Exertional pain and muscle strength were monitored, based on the Medical Research Council score. The exertional pain was completely eliminated in 15 patients (94%). In 5 patients (31%), the strength of the injected muscles remained normal. In 11 patients (69%), strength decreased from 4.5 (out of 5) to 3.5 (P < .01), although without functional consequences. In the conditions of this study, BoNT-A showed a good safety profile in patients with CECS. Conclusion: In this case series, BoNT-A reduced the IMP and eliminated exertional pain in anterior or anterolateral CECS of the leg for up to 9 months after the intervention. The mode of action of BoNT-A is still unclear. A randomized controlled study should be carried out to determine whether BoNT-A can be used as a medical alternative to surgical treatment.
- 22 August 2013
- Published by SAGE Publications in The American Journal of Sports Medicine
- Vol. 41 (11) , 2558-2566
Intramuscular Pressure Before and After Botulinum Toxin in Chronic Exertional Compartment Syndrome of the Leg
Background: Botulinum toxin A (BoNT-A) is used in the treatment of muscle hypertrophy but has never been used in chronic exertional compartment syndrome (CECS). The objective diagnostic criterion in this condition is an abnormally elevated intramuscular pressure (IMP) in the compartment. In this study, the IMP was measured 1 minute (P1) and 5 minutes (P5) after the exercise was stopped before and after BoNT-A injection. Hypothesis: Botulinum toxin A reduces the IMP (P1 and P5) and eliminates the pain associated with CECS. Study Design: Case series; Level of evidence, 4. Methods: Botulinum toxin A was injected into the muscles of moderately trained patients with an anterior or anterolateral exertional compartment syndrome of the leg. The BoNT-A dose (mean ± SD) ranged from 76 ± 7 to 108 ± 10 U per muscle, depending on which of the 5 muscles in the 2 compartments were injected. The primary end point was IMP (P1, P5). Secondary end points were exertional pain, muscle strength, and safety. Follow-up was conducted up to 9 months. Results: A total of 25 anterior compartments and 17 lateral compartments were injected in 16 patients. The time interval (mean ± SD) between the BoNT-A injection and after BoNT-A injection IMP measurement was 4.4 ± 1.6 months (range, 3-9 months). In the anterior compartment, P1 and P5 fell by 63% ± 17% (P < .00001) and 59% ± 24% (P < .0001), respectively; in the lateral compartment, P1 and P5 fell by 68% ± 21% (P < .001) and 63% ± 21% (P < .01), respectively. Exertional pain and muscle strength were monitored, based on the Medical Research Council score. The exertional pain was completely eliminated in 15 patients (94%). In 5 patients (31%), the strength of the injected muscles remained normal. In 11 patients (69%), strength decreased from 4.5 (out of 5) to 3.5 (P < .01), although without functional consequences. In the conditions of this study, BoNT-A showed a good safety profile in patients with CECS. Conclusion: In this case series, BoNT-A reduced the IMP and eliminated exertional pain in anterior or anterolateral CECS of the leg for up to 9 months after the intervention. The mode of action of BoNT-A is still unclear. A randomized controlled study should be carried out to determine whether BoNT-A can be used as a medical alternative to surgical treatment.